ERBB2 and neoplasm: Four (4.6%) patients showed HER2 amplification in the metastasis but not in the primary sample, and 10 (10.6%) patients showed the opposite pattern, with HER2 amplification in the primary tumor but not in the metastasis (Fig. S1).